After a successful career as a pharmaceutical executive at Penwest, Jennifer Good co-founded Trevi Therapeutics in 2011 to address unmet neurological needs in patients with chronic cough and pruritus.
Early Life: Jennifer Good has built a career based on financial acumen, moving from an accounting background into executive leadership within the biotechnology sector.
First Break: Her pivotal career experience was at Penwest Pharmaceuticals, where she rose through the ranks from VP of Finance to COO and eventually CEO before its acquisition.
Path to CEO: Coming off the acquisition of Penwest, Good identified a gap in treatment for specific chronic conditions, co-founding Trevi in 2011 with the goal of bringing novel therapies to market through disciplined clinical development.
Original Vision: To leverage neurological targets to treat chronic, debilitating conditions such as refractory chronic cough and pruritus, addressing significant patient suffering.
Jennifer Good, a CPA by training, pivoted from her successful tenure at Penwest Pharmaceuticals—where she navigated the company to a successful acquisition—to co-founding Trevi Therapeutics in 2011. Her journey is marked by a blend of deep financial rigor and strategic clinical focus. Over her 15-year tenure at Trevi, she has transitioned the company from an angel-financed startup into a publicly traded clinical-stage biopharmaceutical firm, staying singularly focused on advancing Haduvio (nalbuphine ER) through difficult clinical milestones.
co-founderbiotech veterancpamission-driven
